AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Description: Administered as described in the treatment arm
Study NCT02097849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-pegylated interferon
Description: Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
Study NCT02845310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restricted fluid therapy group
Description: Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP >65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP > 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
Study NCT02845310 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard fluid management
Description: Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
Study NCT01911923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No CPAP/PEEP and 100 % oxygen
Description: This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
Study NCT01911923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP and 30 % oxygen
Description: During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
Study NCT04240600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: 2 cans or bottles (200ml)per day, orally
Study NCT04240600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: 2 cans or bottles (200ml)per day, orally
Study NCT01572298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft alone
Description: use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
Study NCT01572298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allograft with autograft
Description: use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
Study NCT01542398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention
Description: A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
Study NCT03015597 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
Study NCT03015597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
Study NCT00443898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
Study NCT00443898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (placebo) applied once daily for 48 weeks
Study NCT00443898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
Study NCT00443898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (placebo) applied once daily for 24 weeks
Study NCT00002644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate 20Mg Tab
Description: Tamoxifen Citrate 20Mg Tab
Study NCT00002644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20Mg Tab
Study NCT03161886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-enteric Capsule Endoscopy (PCE)
Description: Second generation of colon capsule endoscopy (Medtronic)
Study NCT00115037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Study NCT00115037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparer for 16 weeks in phase 2.
Study NCT00115037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management (MM)
Description: Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Study NCT00115037 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medication Management (MM)
Description: Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Study NCT00115037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Description: 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
Study NCT00115037 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Combined Behavioral Intervention (CBI)
Description: 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
Study NCT00115037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
Study NCT01733485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 500 mg/8 h for 5 days
Study NCT01733485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 25 mg/8 h for 5 days
Study NCT00090584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: 4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
Study NCT00090584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: 4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
Study NCT00090584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
Study NCT03151395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sputum and blood sampling
Description: Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
Study NCT04245202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNCOT
Description: The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
Study NCT04245202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: St-FMOT
Description: The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
Study NCT02631070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Study NCT02631070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01432964 — intervention group
Intervention type: PROCEDURE
Intervention: Orbital revision surgery
Description: Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
Study NCT01540136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
Study NCT01540136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
Study NCT01982396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC Twice Daily
Study NCT01982396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC Once Daily
Study NCT01982396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC Once Daily
Study NCT01982396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC Twice Daily
Study NCT01257139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-agent therapy or docetaxel alone or best supportive care
Description: ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management.
Study NCT04094701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Regimen
Description: Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
Study NCT04094701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid reduced regimen
Description: Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
Study NCT03121534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval.
Study NCT03121534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
Study NCT03121534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
Study NCT03121534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
Study NCT02374593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
Study NCT02374593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT04453501 — intervention group
Intervention type: DRUG
Intervention: favorable outcome
Description: Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
Study NCT00706784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Description: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Study NCT01776684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
Study NCT02136498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Standard 12 week course of varenicline, provided in both arms
Study NCT02136498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard 12 week course of varenicline, provided in both arms
Study NCT02136498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help
Description: Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
Study NCT02136498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral self-help
Description: Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
Study NCT02136498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMAP (My Mobile Advice Program)
Description: Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
Study NCT03244241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec 100 UNT/ML [Tresiba]
Description: Basal-bolus insulin regime
Study NCT00678990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of islets with heparin coating
Description: Transplantation of islets with heparin coating
Study NCT01990820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Relieva Balloon Sinuplasty
Description: A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.
Study NCT01990820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy + Maxillary Sinus Irrigation
Description: A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home.
Study NCT01425632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU-284
Description: TAU-284 Low
Study NCT01425632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU-284
Description: TAU-284 High
Study NCT01425632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02963688 — intervention group
Intervention type: GENETIC
Intervention: Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform
Description: BRCA1,2 Germline /Somatic mutation test
Study NCT05765188 — intervention group
Intervention type: OTHER
Intervention: loop electrosurgical excision procedure
Description: A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
Study NCT04055168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
Study NCT04055168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
Study NCT03051490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Study NCT03051490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porcine PERT
Description: oral, enterically-coated, pig-derived, pancreatic enzyme replacement
Study NCT00110760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
Study NCT00110760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
Study NCT04380818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: 200 mg/12h for 5 days
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 200 mg/12h for 5 days
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir/lopinavir
Description: 400/100 mg/12h for 7-10 days
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir/lopinavir
Description: 400/100 mg/12h for 7-10 days
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Injection [Actemra]
Description: 600 mg/day for 1-2 doses
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection [Actemra]
Description: 600 mg/day for 1-2 doses
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg/24h for 3 days